OBJECTIVE: Hysterectomy with concomitant cervical intraepithelial neoplasia (CIN), is often considered a definitive treatment for CIN, but development of subsequent vaginal intraepithelial neoplasia (VAIN) is known to range from 0.9% to 6.8%. STUDY DESIGN: In a retrospective analysis of 3030 women with CIN2+ without history of VAIN in the University Hospital Gasthuisberg, Leuven, Belgium, from January 1989 until December 2003, we identified 125 women who underwent a hysterectomy within 6 months after diagnosis of CIN2+ and reviewed their postoperative Papanicolaou smears. RESULTS: Thirty-one patients (24.8%) were lost to follow-up. Seven of the 94 women in the follow-up group (7.4%) developed VAIN2+, of which 2 were invasive vaginal cancers. Median interval between hysterectomy and diagnosis of VAIN2+ was 35 months (5-103 months). Women with recurrence were significantly older (P = .003). CONCLUSION: Hysterectomy may not be considered as a definitive therapy for CIN2+ because the incidence rate of subsequent VAIN2+ is as high as 7.4%.
OBJECTIVE: Hysterectomy with concomitant cervical intraepithelial neoplasia (CIN), is often considered a definitive treatment for CIN, but development of subsequent vaginal intraepithelial neoplasia (VAIN) is known to range from 0.9% to 6.8%. STUDY DESIGN: In a retrospective analysis of 3030 women with CIN2+ without history of VAIN in the University Hospital Gasthuisberg, Leuven, Belgium, from January 1989 until December 2003, we identified 125 women who underwent a hysterectomy within 6 months after diagnosis of CIN2+ and reviewed their postoperative Papanicolaou smears. RESULTS: Thirty-one patients (24.8%) were lost to follow-up. Seven of the 94 women in the follow-up group (7.4%) developed VAIN2+, of which 2 were invasive vaginal cancers. Median interval between hysterectomy and diagnosis of VAIN2+ was 35 months (5-103 months). Women with recurrence were significantly older (P = .003). CONCLUSION: Hysterectomy may not be considered as a definitive therapy for CIN2+ because the incidence rate of subsequent VAIN2+ is as high as 7.4%.
Authors: Julie S Townsend; Mary Puckett; Cynthia A Gelb; Martin Whiteside; Julia Thorsness; Sherri L Stewart Journal: J Womens Health (Larchmt) Date: 2018-08 Impact factor: 2.681
Authors: Cristina Lamos; Charlotte Mihaljevic; Sebastian Aulmann; Thomas Bruckner; Christoph Domschke; Markus Wallwiener; Carmen Paringer; Herbert Fluhr; Sarah Schott; Christine Dinkic; Janina Brucker; Michael Golatta; Lisa Gensthaler; Michael Eichbaum; Christof Sohn; Joachim Rom Journal: PLoS One Date: 2016-12-01 Impact factor: 3.240